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Abstract
Monoclonal antibody (mAb) has broad applicability in research, diagnosis, 
and treatment. After the introduction of hybridoma technology in 1975, the mAb 
market has increased dramatically, moving a large industry of more than US$ 140 
billions in 2020. In 1954, the concept of the 3R’s was proposed and much changed 
the animal use scenario, including the recent ban on inducing ascites in mice for the 
production of mAb. In light of this, the generation and production of antibodies 
had to be reassessed. In this chapter, we present an overview of the main alterna-
tive technologies to the use of animals in the generation and production of mAb. 
Antibody display libraries and in silico modeling are very promising technologies 
that may provide mAb genetic constructs that, in the sequence, may be expressed 
on mammalian, bacterial, yeast or plant systems. Although the total replacement of 
the use of animals in the entire process is not currently feasible, it is possible to find 
ways to reduce and refine the use of animals in obtaining and producing mAb.
Keywords: monoclonal antibody, alternative methods, antibody generation, 
antibody display libraries, in silico antibody modeling, antibody expression systems
1. Introduction
Animals have been used for research applications since the early centuries after 
Christ [1]. This practice has always been controversial. However, only in 1870, after 
discovering that animals feel pain, the theme began to be reconsidered [2]. Yet, 
the first significant milestone involving ethical issues in using animals for research 
occurred in 1954, when Charles Hume and William Russel proposed the concept 
of the 3Rs. They advocated “Replacing, Reducing and Refining” the use of animals 
to minimize pain or stress whenever possible [3]. This conception was further 
extended to the 6Rs to include “Read across”, referring to the critical analysis of new 
results, “Relevance”, which concerns ethical and educational visions, including good 
laboratory practices, and finally “Roadmaps,” which evolves planning, communica-
tion, conference and technical implementation policies [4]. Recently, the American 
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Anti-Vivisection Society (AAVS) banned the production of ascites in animals, 
launching the “antibodies without animals” campaign [5, 6].
In view of this, the conventionally used strategies to generate and produce 
monoclonal antibodies (mAbs), initially proposed by Köhler and Milstein in 1975 
[7] as the hybridoma technology, had to be reconsidered. This methodology is based 
on the immunization of animals with the antigen of interest, followed by the fusion 
of B lymphocytes with myeloma cells, resulting in the formation of hybridomas. 
After cloning and selection, the antibody-secreting stable monoclonal cell lines 
were used to produce mAb-enriched ascitic liquid [8], a now-banned practice. 
For many years, mAbs, which have wide applicability in research, diagnosis, and 
treatment, were generated and produced with this methodology. In this chapter, the 
main technologies that emerged as alternatives to the use of animals for the genera-
tion and production of mAbs are discussed.
1.1 Overview of antibody structure and most common formats
mAbs are immunoglobulin molecules with a molecular weight of ~150 kDa, 
made up of four polypeptide chains: one pair of identical light chains and another 
pair of identical heavy chains joined by disulfide and non-covalent bonds. Each 
chain contains a variable domain (VL and VH) at the N-terminal portion and one 
or three constant domains at the polypeptide’s C-terminal portion. The antigen-
binding fragment (Fab) has ~50 kDa and is composed of variable and constant 
regions of heavy and light chains. The variable fragment (Fv) includes only the two 
variable domains of both chains (Figure 1a) [9]. Each variable region is composed 
Figure 1. 
Schematic representation of different antibody formats: (a) the classic IgG and its respective regions and 
chains; (b) monovalent antigen-binding formats: Fab and scFv; (c) bivalent antigen-binding formats: Fab’2, 
diabody and minibody. Different textures indicate different antigen specificities; (d) structures composed of 
scFv can form diabody, triabody and tetrabody; (e) other possible formats that can be constructed; (f) camelid 
Ig and shark IgNAR molecules.
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of six complementarity determining regions (CDRs), also known as hypervariable 
regions: three in the light chain (L1, L2, and L3) and three in the heavy chain (H1, 
H2, and H3), CDR H3 being the most variable in length, sequence, and structure. 
These regions promote the high specificity of functional binding of mAbs with the 
target antigen [10]. In spite of hypervariable regions, it should be noted that these 
regions assume conformations in the form of loops because of the presence of some 
conserved residues [11].
There are several formats of antibodies used for therapeutic, diagnostic, and 
basic research purposes. Smaller formats were initially generated by the removal of 
the constant domain (Fc) by proteolysis, with the enzymes papain and pepsin, and 
later by genetic manipulations, giving rise to monovalent antigen-binding formats: 
Fab and scFv (variable single-chain fragment) (Figure 1b) or bivalent formats such 
as Fab’2, diabody, minibody, among others (Figure 1c). These antibodies present 
characteristics in comparison to complete mAbs that may be useful depending 
on the application: besides retaining the antigen-binding affinity of the parental 
antibody, they have a reduced serum half-life and are less immunogenic [12, 13]. In 
addition to conventional shapes, camelids and sharks produce unusual antibodies 
composed only of heavy chains, with just a single domain in its variable antigen-
binding site. In Camelidae, it is called variable domain of heavy chain antibodies 
(VhHs), while in some cartilaginous fish, like sharks, it is called new variable 
antigen receptor (V-NARs). The smaller sizes of VhHs and V-NARs allow them to be 
good candidates as biotechnological tools (Figure 1f) [14–16].
Fab favors the crystallization of several proteins facilitating the determination of 
their three-dimensional structure [15]. Therapeutic Fabs have been available since 
1994, starting with the chimeric abciximab Fab (ReoPro), used as an antiplatelet 
agent. Ranibizumab (Lucentis) was approved by Food and Drug Administration 
(FDA) in 2006 for treatment of age-related macular degeneration, certolizumab 
pegol (Cimzia) was approved in 2009 for rheumatoid arthritis, and several other 
Fabs are now in clinical and pre-clinical trials. This format is also useful for diag-
nostic imaging, like arcitumomab (CEA-scan) approved in 1996 for colorectal 
cancer screening [12, 17, 18].
Another variant is scFv antibodies, with a molecular mass of ~30 kDa, com-
posed of VH and VL domains joined with a peptide ligand. These structures can be 
presented as dimers, trimers, tetramers (Figure 1d) or other formats (Figure 1e) 
through genetic or chemical manipulations. Diabodies can present two identical 
antigen-binding sites, when it is called a bivalent diabody, or have two different 
antigen-binding sites, a bispecific diabody [19, 20]. Numerous scFvs have been con-
structed against haptens, proteins, carbohydrates, receptors, tumor antigens, and 
viruses for applications in therapy and diagnosis [21]. In 2019, the FDA approved 
the humanized scFv brolucizumab (Beovu) to treat neovascular age-related macu-
lar degeneration. Other scFvs are already in a pre-clinical study for targeted cancer 
therapy [22].
2. Alternative methods for monoclonal antibody generation
2.1 Antibody display libraries
Antibody display libraries are powerful tools to isolate high-affinity antibod-
ies for therapeutic and/or diagnostics applications. They can be divided into two 
groups: cell surface and cell-free display libraries. In the first case, the antibody 
is expressed on the surface of bacteria, yeasts, or mammalian cells, using own 
internal machinery [22] and, in the second, extracts of prokaryotic or eukaryotic 
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cells, mainly from rabbit or wheat germ, are used to transcribe and translate 
genetic information contained in the library [23, 24]. Although they use different 
paths, these methodologies have a common property: they are potential alternative 
methods to the use of animals for antibody generation.
These methodologies involve two main steps: the construction of the library 
and the selection of the antibody of interest. According to the origin of the genetic 
material used in their construction, the libraries are classified as naïve, immune, 
synthetic, or semi-synthetic. The immune library is obtained from animals or 
humans that have been immunized and developed antibodies against a particular 
antigen [25, 26]. The other types are known as universal libraries: naïve is cloned 
from non-immunized donors; the semisynthetic is created using both naturally 
and synthetically (in silico) randomized CDRs, which increases the diversity of the 
library without requiring a large number of donors; and synthetic, based only in in 
silico design and gene synthesis to optimize individual amino acids, hence expand-
ing its diversity, expression, and stability [27].
2.1.1 Cell surface display
Among the display libraries, the phage display stands out for being the first 
described and currently more used in the generation of antibodies [28]. The tech-
nique was developed by George Smith in 1985 and it uses the bacteriophage’s ability 
to infect bacteria. In this way, a foreign DNA sequence is inserted into the genes III 
or VIII, which encode the pIII and pVIII coat proteins, respectively. The recombi-
nant protein is displayed on the outer surface of the phage as a fusion protein in an 
immunologically accessible form [29]. The displayed antibodies can be of either 
Fab or scFv formats. The phage display library is generated by assembling DNA 
sequences that encode antibody fragments in the phage or phagemid vectors. The 
phage vector has a complete phage genome, but it is not effective for large proteins. 
A phagemid vector is a plasmid that contains phage coat gene (gIII or gVIII), and 
phage and plasmid’s origin of replication. The vectors are used to transform E. coli. 
The phage vector has all the ability to produce phage particles and display the fusion 
antibody, while the phagemid needs to infect the bacterium with a helper phage to 
enable the recombinant DNA package, as a single-strand DNA into virion particles, 
and to display the antibody fragments [25, 28, 30]. The screening of displayed 
antibodies is performed by biopanning, a process in which the phages are incubated 
with the immobilized antigen, and the non-binding phages are removed by exten-
sive washing. The bound phages are then eluted and enriched by reinfection of 
E. coli and thus successive rounds of selection can be carried out as many times as 
needed [31].
Bacterial display, an alternative to phage display, allows libraries of greater 
diversity. In this system, the expression of recombinant proteins is easier and the 
transformation by DNA is more efficient than phage display. The methodology is 
fast, easy to handle, and eliminates the stage of infection by the phage. The library 
can be displayed on the membrane in the periplasmic space or fused to the filament 
flagellar or fimbrial adhesin proteins [32, 33]. To generate the bacterial library, the 
sequences of DNA, encoding scFv or Fab fragments, are inserted into the appropri-
ate display vector used to transform E. coli, the most common bacterial strain used 
in this technique [34]. The target antigen, adsorbed on magnetic beads or fluoro-
phore-labeled, is used for the screening of antibody libraries by cell sorting [35].
In the cases of yeast and mammalian displays, eukaryotic systems, folding and 
post-translational modifications, which are relevant to the function and stability 
of the antibody, are more effective when compared to what occurs in the pro-
karyotic system [22]. Briefly, the yeast library is created by linking the antibody 
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gene sequence into suitable yeast display vectors. The transformed yeast by the 
plasmid generated is induced to express the recombinant library. The system can 
display scFv, Fab, or full-length antibody formats [36], that are expressed in fusion 
with anchor proteins of the glycosylphosphatidylinositol (GPI) family, such as 
α-agglutinin and a-agglutinin. The screening is performed by cell sorting [37].
When using the mammalian system, the post-translational modifications are 
still more effective than those possible in the yeast system. The antibody library 
can be usually displayed on the surface of Human Embryonic Kidney 293 T (HEK 
293 T) and Chinese Hamster Ovary (CHO) cells after transient or stable trans-
formation [38]. The antibody expressed is fused to the transmembrane domain 
of human platelet-derived growth factor receptor (PDGFR), which anchors the 
antibody on the outer surface of the cell membrane [39]. The library screening is 
performed as already described for other cell-surface display systems [40].
2.1.2 Cell-free display
The cell-free display libraries, unlike previously described ones, do not depend 
on the efficiency of transduction or transfection. Among them, the ribosome and 
mRNA systems have been the most described, offering around 1012–1014 variants, a 
wider diversity over other display techniques, like phage (around 109), eukaryotic 
(106–107), and prokaryotic (108–1010) systems [41].
While the ribosome display connects nascent proteins to their encoding mRNA 
through the generation of stable protein–ribosome–mRNA complexes, the mRNA 
system uses an antibiotic, puromycin, that mimics the structure of an aminoacyl-
ated tRNA, to modify mRNA that also is linked to its respective nascent protein. In 
a brief description, a ribosome system display construct is designed to be used with 
cell extracts to allow the downstream mRNA synthesis. In the construct, it must be 
present a ribosome binding site to the start codon where protein synthesis begins, 
for recruitment and pairing of the ribosome. The open reading frame is followed by 
the library of binding proteins and a spacer. The spacer provides flexibility to the 
display library in order to fold outside of the ribosome tunnel. Another important 
point is that the ribosome is stalled at the 3′-end by deleting the stop codon to 
couple the nascent polypeptide with its encoding mRNA [23, 42, 43].
The mRNA display stands out in relation to the ribosome display for offering a 
large degree of control over experimental conditions [41]. Briefly, the DNA anti-
body library is in vitro transcribed in mRNA. In a second step, a covalent interaction 
between mRNA and puromycin is produced, providing after translation the forma-
tion of the mRNA-puromycin-protein complex, which is reverse transcribed into 
cDNA to obtain the heteroduplex cDNA-mRNA, more stable than mRNA alone. 
After screening, the selected cDNA is amplified by PCR. The amplified constructs 
are subjected to a new cycle to obtain the mRNA-puromycin-protein complexes, and 
then the heteroduplexes obtained are ready for a new round of screening [41, 43].
Both methodologies enable the generation of different formats of the antibodies, 
including the full-length ones. The selection of the antibodies of interest is per-
formed by binding to an immobilized antigen. Ribosome and mRNA systems have 
gained relevance for allowing efficient and low-cost antibody production and for 
their advantageous ability to screen large libraries. Although promising, so far there 
is no commercially available antibody generated by cell-free technologies.
2.2 Antibody design via in silico modeling
Advances in DNA and protein sequencing techniques associated with X-ray 
crystallography approaches to evaluate the antibody structure at an atomic level 
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and the increasing availability of the generated data in public domains provided a 
fundamental basis to the in-silico generation of mAbs.
Computer-assisted design of new mAbs consists of high-throughput algorithm 
analyses of antibody structures modeled from query residue sequences. These 
models are typically obtained by homology with precompiled antibody scaffold 
templates [44], which is possible because, despite the unique spatial identity of 
mAbs, the geometry of their variable regions is well conserved, with most CDR 
loops having a limited number of conformations, known as canonical classes [11]. 
In general, the established modeling tools coupled with refined protein–protein 
docking [45] and machine learning methods have been found useful for predict-
ing the VH and VL domain arrangements and the potential antibody electrostatic 
complementary interface [46].
Examples of platforms available for antibody modeling are the “Prediction of 
ImmunoGlobulin Structure” (PIGS) [47], the Rosetta Antibody Modeling [48], and 
the “Web Antibody Modeling” (WAM) [49]. These servers comprise fully auto-
mated homology-based modules that predict with high accuracy the tridimensional 
antibody structure, including most of the hypervariable regions of the antigen-
binding site [50]. An exception is the H3 loop. Unlike the other CDRs, the H3 
structure has unique conformations that do not follow a canonical form and are also 
not found in any described protein, with ~75% of its fragments not having struc-
tural neighbors in the known non-immunoglobulin protein world [51]. Therefore, 
the H3 loop cannot be predicted by selecting templates from a database and this is 
an important obstacle for the in silico antibody design. Some alternative algorithms, 
based on candidate conformations obtained computationally and energy functions, 
have been developed, but they often fail to produce sub-angstrom structure models 
[50, 52] and the problem persists.
Other concerns also affect antibody modeling. The limited number of high-
quality X-ray crystal structures of mAbs in public protein databases may not be 
sufficient to allow a proper antibody shape prediction [50]. Regarding the docking 
protocols, it should be noted that, despite the great advances in the bioinformatic 
field, most of the antibody algorithms still need to be optimized to consider the 
molecular backbone flexibility and the transient conformational changes following 
protein–protein interactions [53, 54]. Another relevant point is the time needed for 
antibody modeling. High-throughput computational design of mAbs can still be as 
time-consuming as experimental cellular approaches, even when well-consolidated 
prediction systems are used. As an example, the Rosetta Antibody server was previ-
ously found to take 570,000 CPU hours to generate ~2,000 antibody models [55].
With many challenges ahead, currently there are few reports of functional 
antibodies completely designed by in-silico approaches. A successful attempt in this 
field is the mAb described by Nimrod and co-workers, which was based on robust 
predictions of specific residue-residue interactions rather than modeling the entire 
antigen–antibody complex [56]. On the other hand, computational protocols have 
been used with increasing frequency to improve the physicochemical properties of 
previously generated mAbs, as well as to engineer humanized versions of murine 
full-length immunoglobulins, making them like those found in humans [57]. 
Molecular structure-based iterative algorithms have been shown to optimize the 
generation of humanized antibody scaffolds without a significant drop in affinity 
and specificity toward the antigen, compared to the original murine one, and with 
reduced occurrence of structure failures, important drawbacks commonly found 
following conventional humanization techniques, which are mostly guided by 
linear antibody residue sequences [58].
The overall computational antibody discovery scenario is promising and, 
although the design of new biologically active mAbs is still deeply dependent on 
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living animals, the advances in structure prediction methods set the scene for an 
ongoing technological evolution that should potentially lead the future generation 
of these molecules using only in-silico approaches.
3. Alternative methods for mAb production
3.1 Mammalian production systems
As previously mentioned, one of the major utilities of the mammalian expression 
systems is to produce complex biomolecules such as antibodies that require post-
translational modifications like glycosylation [38]. Though other eukaryotic systems 
do provide this modification, their capability of doing so is limited and might result 
in the addition of glycans that are not common in human proteins [59]. This event 
might result in misfolding and biologically inactive immunoglobulins, undesirable 
features in human therapeutic and diagnostic monoclonal antibodies [60]. Also, 
expression in prokaryotic systems might lead to contamination with endotoxins, 
which increases downstream processes to clear these endotoxins from the final 
product. Thereby, the mammalian expression systems are valuable tools to produce 
monoclonal antibodies as well as other proteins with proper structure and activity. 
Indeed, there are numerous FDA-approved mAbs produced in mammalian expres-
sion systems in contrast to prokaryotic systems and other eukaryotic cells [61].
The primary technique for mAb obtention was already originally dependent on 
a mammalian cell: the hybridoma cell [7]. As the high specificity of the monoclonal 
antibodies was making these molecules increasingly useful for various applica-
tions, a hybridoma large-scale cultivation became a great demand in the industry. 
Therefore, the ascites method production was no longer enough to supply bulk 
production, nor feasible due to ethical matters. That way, most research and diag-
nostic proposed mAbs are now produced in vitro, through the harvest and following 
purification of mAb-enriched media obtained in dynamic or non-dynamic cell 
culture systems [62].
In a therapeutic context, although the hybridoma cell lines are still responsible 
for the generation of more than 50% of the FDA-approved mAbs [63], these anti-
bodies are bulk produced in other mammalian host systems [64]. This is due mainly 
to the highly immunogenic nature of murine mAbs for humans, demanding the 
antibodies to be genetically modified (humanization or generation of fragments) 
for human therapeutic use [65]. Besides, many of these mammalian cells had their 
expression machinery highly optimized for recombinant protein production [66].
In the mammalian expression system, cells are readily transfected or transduced 
to introduce foreign DNA that codes for the target protein and then, they are culti-
vated preferably in suspension in a chemically defined serum-free media [59].
The preferred mammalian cell lines for protein expression in research and 
industrial fields are CHO and HEK-293 cells [67]. CHO cells are dominant in 
heterologous protein production in industry, mainly because of advantages like the 
property to provide complex post-translational modifications similar to those of 
humans, their ease to scale-up, and for being easily adapted to grow in serum-free 
suspension cultures [65]. CHO cells are more suited for stable expression, for its 
transfection renders low yields of recombinant protein secretion in this lineage. 
Since establishing a stable cell line is time and labor-consuming, transient trans-
fection is a suitable option to gather high amounts of proteins in a shorter period. 
In this case, HEK cells might represent an interesting option, since they are well-
known for being rather suitable for transient transfection. This cell line also has 
rapid doubling time and grows in high-density concentrations, just like CHO cells, 
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and presents productivity of grams of protein per liter of culture [67, 68], though 
they have somewhat more tendency to clump [69, 70].
The PER.C6 cells are human embryonic retinal cells, and like HEK cells are 
pointed out to promote human glycosylation profiles. They were projected to be 
grown in high-density conditions [71], with stable expression and also offer pro-
duction yields similar to CHO cells, indicating that human cell lines will be more 
economically viable and more easily scalable options for antibody productions [72]. 
There is even description of a production with titers of 27 g/L of antibody, astound-
ing yields when compared to a medium CHO cell production of around 12 g/L of 
antibodies [73]. Although there is still no FDA-approved mAb produced in this 
system, there are already some ongoing clinical and preclinical studies carried out 
with mAbs and other biological products purified from this system, like vaccines 
for influenza, HIV, and Ebola [74–77].
There are other suitable host cell lineages such as murine lymphoid cell lines like 
NS0 and Sp2/0-Ag14, derived from BALB/c mice plasmocytomas, corresponding 
for almost 25% production systems of FDA-approved monoclonal antibodies. One 
of their major advantages is being originated from naturally high immunoglobulin 
producing parental cells. Though, their murine origin is not to be underesti-
mated, for there are reports that they do generate immunogenic glycoforms of the 
expressed antibodies [78].
Concerning the expression vectors for mAb production, usually the plasmids 
carrying the heavy and light chain genes are constructed based mainly into two 
kinds of systems: the dihydrofolate reductase (DHFR) system or glutamyl synthe-
tase (GS) based system, both acting as selection markers [65]. In DHFR, selection 
occurs through glycine, hypoxanthine, and thymidine depletion from the cell 
culture medium. Selected clones are subjected to the addition of methotrexate, a 
folate analog that poisons the cells deficient in DHFR, obliging the cells to further 
synthesize the enzyme with consequent co-amplification of the IgG genes. In the 
GS system, the selection is done in the absence of glutamine, in a way that only cells 
with GS can survive by synthetizing glutamine from glutamate and ammonium. 
Here, the selective pressure is made through increasing doses of the GS inhibi-
tor methionine sulfoximine, pushing the cells to amplify GS and IgG genes [79]. 
Promoter characteristics, inclusion of antibiotic resistance genes, transcription 
termination sequences [poly(A)], and translation control sequences should also be 
taken into account when designing these vectors [80].
In comparison to other production systems, mammalian cells are more fastidi-
ous to culture than bacteria and fungi, for they are larger and do not possess tough 
cell walls like other microorganisms, making them more sensitive to impurities 
naturally occurring from the production system itself. Having them to thrive and 
reproduce in culture after modifications to turn them stable and in conditions to 
secrete the aimed molecule with high yields is a challenge in itself [61, 67]. If one is 
not choosing for the transient transfection, having the stable lineages may also be 
costly and time-consuming.
Independent of the expression system, the correct choice of the production scale 
should be made accordingly to the given necessity. The simplest culture system 
is the static culture, consisted of T bottles with screw caps kept horizontally in 
an incubator. Because of its low maintenance profile and low costs, it is the most 
widely used culture method in the academic research context. It is possible to use 
this system for clone screening and determining experimental conditions, but its 
small-scale nature might not render enough mAb quantity for some other types of 
assays. An option to circumvent this matter might be the use of the rolling systems 
that offer a medium-scale mAb yield. In this condition, roller bottles are positioned 
in a rotation system that causes all cells to be in constant movement, and therefore, 
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all of the components of the culture (cells, nutrients, dissolved gases, and metabo-
lites) are uniformly distributed throughout the volume of the medium. This system 
requires gradual adaptation to cell growth in suspension, starting from very low 
rotation speeds [81–83].
Currently, the bulk production of mAbs in agitated bioreactors is the predomi-
nant cell culture system in the industry because it allows constant control and 
monitoring of the process. The area of  research for innovation in these bioreactors 
has advanced dramatically. In general, bioreactors are used to achieve high cell 
densities and thus increase the production of monoclonal antibodies, biopharma-
ceuticals, and vaccines [84]. Different types of agitated bioreactors have been used 
for the cultivation of mammalian cells, both on a pilot and industrial scales.
3.2 Bacterial and yeast production systems
The use of microorganisms such as bacteria and yeasts is widely used in science 
for several purposes, generally related to antibiotics and probiotics [73]. However, 
both bacteria and yeasts have been getting space in the production of mAbs for 
immunological therapy due to the biopharmaceutical demand and technological 
advances about their ability to produce antibodies by reducing the use of animals 
in the manufacturing process [73]. The motivation behind investments that seek 
to optimize the means of production of mAbs in alternative models stems from the 
manufacturing disadvantages presented in the traditional method with mammalian 
cells, which have been predominantly employed in the expression of these antibod-
ies due to their ability to introduce post-translational modifications similar to those 
human cells [85]. The mammalian expression system is expensive and time-con-
suming, and efforts have been made to express them in different systems. Microbial 
cells of yeasts and bacteria have many advantages, such as typical rapid growth, low 
cultivation costs, and genetics well known in the literature [86]. Microorganisms 
can produce high molecular weight compounds like proteins, perform highly 
selective reactions by their native enzymatic machinery, and also allow the repeated 
introduction of enzymes or immobilized cells [87]. In addition, finally, processes 
that use microorganisms do not generate organic and inorganic pollutants, such as 
mercury and toluene [88]. Still, it was complicated to produce complete antibodies 
in prokaryotes to the detriment of the insecurity of microbial products for human 
use [73]. Fortunately, the FDA published a special set of rules called “Generally 
Recognized as Safe” (GRAS), which guarantees the human safety of microbial 
products and the production of monoclonal antibodies [89]. Thus, several microor-
ganisms were explored. In the case of gram-negative bacteria, Escherichia coli stands 
out, once it has two compartments for protein expression - the cytoplasm and the 
periplasmic space [86]. Gram-negative bacteria also have an oxidizing environment 
which allows the correct formation of disulfide bonds [90].
Whole antibodies can be produced in bacteria and this process is dependent 
on periplasm, which is an essential region for folding the proteins and chains that 
make up the structure of antibodies. Unfortunately, studies reveal very low levels of 
periplasm, which limits the yield for mAbs production [91]. Efforts to produce anti-
bodies in the cytoplasm have not been successful until recently [92]. Gram-positive 
bacteria are more advantageous than gram-negative bacteria because they do not 
produce endotoxins - a highly immunogenic lipopolysaccharide (LPS) produced 
by gram-negative bacteria. Fewer complex eukaryotes such as yeasts have also been 
exploited for the production of mAbs. They have the advantage over prokaryotes 
in similarity with the mammalian protein expression system, allowing the expres-
sion and folding of complex proteins more easily, and yet, as well as gram-positive 
bacteria, do not produce endotoxins [93].
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Among yeasts, Pichia pastoris and Saccharomyces cerevisiae dominate the field in the 
production of antibodies [86]. S. cerevisiae is promising due to the advantage of being 
well characterized, but the correct folding of chains and proteins and low yields are 
problems to be faced. On the other hand, P. pastoris does not secrete many endogenous 
proteins that need to be removed in the mAbs production process [94]. Yeasts have cel-
lular glycosylation machinery, however, their proteins exhibit types of glycosylation 
completely different from human proteins, and this results in a significant reduction 
in therapeutic effector functions [95]. Whether from yeasts or bacteria, native full-
length mAbs need to be glycosylated during their synthesis, but this is an obstacle that 
has yet to be overcome for better production efficiency in microbial hosts. The glyco-
sylation status of the Fc region is critical for the recruitment of serum proteins from 
the complement system and the destruction of target cells by complement-dependent 
cytotoxicity (CDC) cascades [95]. This is the main reason why the method of produc-
ing mAbs in mammalian cells is still the most applied [91]. Until 2020, there are 151 
recombinant therapeutic proteins approved by the FDA, one-third of them are mAbs 
but there are many other mAbs under development. Among these mAbs, only two are 
antigen-binding fragments (Fabs) that are produced in the periplasm of the bacteria 
E. coli: ranibizumab and certolizumab pegol. The first, ranibizumab, approved in 
2006, is an IgG1 Fab fragment used to treat neovascular age-related macular genera-
tion and macular edema after retinal vein occlusion. Certolizumab pegol is also a 
humanized Fab fragment, approved in 2008 for the treatment of Crohn’s disease and 
rheumatoid arthritis. Therefore, since the advent of mAb therapy, the biopharmaceu-
tical industry has been investing considerable resources in new bioprocesses for the 
manufacture of glycosylated antibodies that attach human IgG-like glycans through 
alternative host expression [95].
3.3 Plant-based antibody production systems
To produce antibodies in plants, a transformation is mediated by a bacterium 
that infects plants, called Agrobacterium. The bacterium then loads the expression 
vector with the antibody gene, thus generating the transgenic plants that express the 
desired antibody. The transformed Agrobacterium is inoculated into the leaf slices of 
the plants. These slices regenerate in 3–4 weeks. Small shoots are then formed from 
the callus and transferred to a plant cultivation box in vitro. For the production of 
biomass, in vitro transgenic plants are transferred to a soil pot and grown in a green-
house [96]. The most used plant systems are tobacco and alfalfa because they are the 
most accessible and common sources of leaf biomass. Tobacco has great advantages, 
such as high leaf biomass yield and rapid scaling up through easy seed production 
compared to other plant species. However, tobacco contains nicotine and other toxic 
alkaloids that need to be removed through an additional extraction step [97].
The plant system offers important advantages, such as high production capacity, 
low cost in the large-scale cultivation process, in addition to avoiding ethical prob-
lems associated with animals [98]. Another important advantage of using this system 
is found in post-translational protein modifications, which occur in plant cells in a 
similar way to animal cells, as well as in the correct assembly of complex molecules, 
such as antibodies, are aided by chaperones that mediate folding and the formation 
of disulfide bonds, while the addition of N-glycans is carried out by specific cellular 
glycosyltransferases. In fact, while core N-glycans are similar in plants and mammals, 
complex N-glycans show substantial differences with sialic acid [99–101].
In addition, there is a possibility to design a custom antibody glycosylation 
profile, and production can be enlarged simply by increasing the number of 
plants [102]. In comparison with the systems described earlier, the use of plants 
for the production of antibodies offers several irreplaceable benefits. Plants are 
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widespread, abundant, and develop more quickly because they normally mature 
after a growing season. It is possible to put the product on the market quickly, which 
ends up decreasing the cost of production. Plants also reduce screening costs for 
bacterial toxins, viruses, and prions because they are less likely to introduce animal 
pathogens than mammalian cells or animals [98].
The disadvantages of this system are found in the low yield of protein expres-
sion, the downstream processing problems related to the extraction of proteins 
from leaves, and some regulatory obstacles [103].
The first pioneering study on the production of full-size IgG in plants dates 
back almost 30 years ago [104]. Since then, different antibody formats have been 
expressed in plants, such as IgA, Fab fragments, minibodies, and scFvs [103]. The 
first drug from plant cells to receive FDA approval for human use was the enzyme 
β-glucocerebrosidase, commercially called ELELYSO, indicated for the treatment 
of patients with a confirmed diagnosis of Type 1 Gaucher disease [105]. Thereafter, 
Medicago Inc. developed a quadrivalent plant-derived seasonal influenza vac-
cine that recently completed Phase III clinical trials [106]. A study published in 
September 2020 positively demonstrated the expression of a scFv 13F6 antibody 
with binding activity against Ebola virus-like particles in a plant system [107, 108]. 
Of the antibodies produced by plants, there are already 6 against viruses, 5 against 
tumors, and 3 against bacteria [97].
Therefore, given the data presented and the clear advantages, we can say that the 
plant system is quite efficient and may, in the future, be widely used in the produc-
tion of antibodies both in basic research and on an industrial scale.
4. Conclusions
Bearing in mind that obtaining high specificity and affinity mAbs is not trivial, 
there is a great race to develop methodologies that can meet the most varied demands. 
An overview of the main technologies clearly shows that the total replacement of ani-
mals’ use in the generation and production of mAbs is not possible for the moment. 
We believe that this will only be reached when the in silico technology is fully domi-
nated. But as the implementation of alternative methods must be seen as a process, 
reducing and refining the use of animals are achievements. Thus, the different types 
of antibody display libraries represent a major breakthrough. As described, the source 
of genes for building the libraries may imply greater or lesser use of animals and only 
synthetic display libraries completely dispense the use of animals. In the same way, 
for the production of mAbs, several possibilities are currently available. The impor-
tant thing in the production stage is that the use of ascites, a proceeding that brings 
pain and stress to animals, may already be eliminated in most cases. Invariably, the 
purpose and amount of the mAb to be produced will determine the choice of obtain-
ing and production methodologies. Given the great utility and diversity of mAb uses, 
ranging from therapeutic application to essential research tools, and the wide range 
of technologies available today for obtaining and producing them, it seems a fact that 
it is always possible to choose or design a path that meets the concept of 3Rs.
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